2019 American Transplant Congress
FcγRIIB is a Novel CD8+ Effector T Cell Intrinsic Regulatory Pathway That Correlates with Freedom from Rejection in Renal Transplant Patients
*Purpose: To understand the functional role and clinical relevance of FcγRIIB on CD8+ T cells in transplantation.*Methods: See results*Results: FcγRIIB is the sole inhibitory Fcγ…2019 American Transplant Congress
IFNAR Signaling Augments Plasmacytoid Dendritic Cell Activation during Costimulation Independent Rejection
Surgery, Emory University, Atlanta, GA
*Purpose: Costimulation blockade (CoB) is a promising new transplant immunosuppression strategy offering improved long-term patient and allograft survival without the nephrotoxicity of calcineurin inhibitors. However,…2019 American Transplant Congress
The Use of mTOR Inhibitors Prevents Acute Cellular Rejection in Kidney Transplantation on Belatacept Therapy
University of California San Francisco, San Francisco, CA
*Purpose: Belatacept is a costimulatory blocker that is used as de novo maintenance immunosuppression in kidney transplantation to avoid toxic effects of calcineurin inhibitors and…2019 American Transplant Congress
Memory T Follicular Helper Cell Alloresponse is Memory B Cell Independent and Inhibited by CD28 Costimulation Blockade
Emory University School of Medicine, Atlanta, GA
*Purpose: Donor-directed HLA antibodies are an important cause of renal allograft injury, but reliable and durable therapeutic options to prevent or eliminate donor-specific antibodies (DSA)…2019 American Transplant Congress
In Vivo Treg Expansion under Costimulation Blockade Targets Early Rejection and Improves Long-Term Outcome
*Purpose: Early rejection episodes are a major problem under CTLA4Ig/belatacept-based immunosuppression. We have previously shown that CTLA4Ig therapy is dependent on Tregs at low (LD)…2019 American Transplant Congress
Belatacept Based Simultaneous Calcineurin Inhibitor Avoidance/Early Corticosteroid Withdrawal is Associated with Low New Onset Diabetes Risk
*Purpose: Calcineurin inhibitor (CNI) and/or corticosteroid (CCS) therapy are associated with significant risk of new onset diabetes after transplantation (NODAT). An important consideration for simultaneous…2019 American Transplant Congress
CNI-Free Therapy with Iscalimab (anti-CD40 mAb) Preserves Allograft Histology Compared to Standard of Care after Kidney Transplantation
*Purpose: To assess if calcineurin (CNI)-free therapy with iscalimab preserves the quality of transplanted kidney grafts.*Methods: Iscalimab (CFZ533) is a new, fully human, Fc-silenced, non-depleting,…2019 American Transplant Congress
Early T Cell Infiltration is Modulated by PD-1/PD-L1 Interactions in Kidney Graft
Inflammation and Immunity, Lerner Research Institute, Cleveland, OH
*Purpose: Allogeneic transplants elicit dynamic T cell responses that are modulated by positive and negative co-stimulatory receptors. We have investigated the impact of PD-1, a…2019 American Transplant Congress
The mIR17-92 Cluster Promotes Costimulation Resistant Effector Memory T Cell-Mediated Alloresponses
1Surgery, Duke University, Durham, NC, 2Immunology, Duke University, Durham, NC
*Purpose: CD57 expression has been shown to identify a subset of memory T cells that are resistant to CD28/B7 costimulation blockade (B7CoB). This study was…2019 American Transplant Congress
Dual Treatment of CD40 Silencing or Mesenchymal Stem Cells Infusion with Sub-Therapeutic Doses of Cyclosporine Effectively Prevents Acute Rejection in an Allogenic Model of Renal Transplantation
*Purpose: This study was designed to investigate the combination of CD40 silencing or MSC infusion with suboptimal doses of Cyclosporine in this renal allograft model.*Methods:…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 30
- Next Page »